Stoke Therapeutics
STOK
67 hedge funds and large institutions have $791M invested in Stoke Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 9 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 15
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
5% more funds holding
Funds holding: 64 → 67 (+3)
2.62% more ownership
Funds ownership: 102.3% → 104.92% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $948M → $791M (-$157M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$28.3M |
| 2 |
BlackRock
New York
|
+$11.2M |
| 3 |
AG
Artal Group
Luxembourg
|
+$6.18M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.94M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$14.5M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.66M |
| 3 |
Millennium Management
New York
|
-$5.16M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$4.06M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$3.46M |
STOK Hedge Fund Activity: Q1 2020 in Review
67 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2020, worth a combined $791M — down 17% from $948M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new STOK positions and 9 closed out — a net gain of 3 holders — while 29 added to existing stakes and 15 trimmed.
The largest buyer was Redmile Group, adding an estimated $28.3M. The largest seller was Janus Henderson Group, cutting an estimated $14.5M.
- 67 institutional investors held Stoke Therapeutics (STOK) as of Q1 2020, up from 64 in Q4 2019.
- Funds reported $791M of Stoke Therapeutics stock for Q1 2020, down 17% quarter-over-quarter.
- 12 funds opened new Stoke Therapeutics positions in Q1 2020 and 9 closed out, a net change of +3 holders.
- The largest Stoke Therapeutics buyer in Q1 2020 was Redmile Group, an estimated $28.3M added.
- The largest Stoke Therapeutics seller in Q1 2020 was Janus Henderson Group, an estimated $14.5M sold.
Based on aggregated 13F filings for Q1 2020.